The Chad Carr Pediatric Brain Tumor Center is committed to pushing the limits of what is known about pediatric brain tumors, and advancing treatment for children with these diseases.
Thanks to contributions to the U-M ChadTough Fund and the incredible efforts of the ChadTough Foundation, the Chad Carr Pediatric Brain Tumor Center has established a Proof of Principal Research Collaboration (P3RC) Award.
P3RC awards are granted to projects in our priority research areas of drug delivery, device deployment, clinical trials, cellular therapy and immunotherapeutics, and are designed to bring University of Michigan investigators from complimentary fields together to work on research strategies and approaches to cure DIPG. All funding recipients agree to share data with other Chad Carr Pediatric Brain Tumor Center research faculty.
Proposals for P3RC Awards are accepted on a rolling basis, are reviewed, then presented to the CCPBTC Advisory Committee for funding determination. Funding awards are determined through peer-review using internal and, where appropriate, external reviews to ensure funds support innovative projects that can be feasibly accomplished.
View the current RFA for proposal guidelines and submission instructions. Applications are accepted through Competition Space. The CCPBTC Advisory Committee meets quarterly ( Jan, Apr, Jul, Oct) to review proposals. For additional information or questions regarding the application process, please contact Falicia Modrzynski in Pediatric Hematology Oncology at [email protected] or at 734-647-2893.
2019 Funded Projects
Expanding the Clinical Trial Capacity of the Chad Carr Pediatric Brain Tumor Center
(clinical trial)
Principal Investigator(s): Andrea Franson, MD, MS
U-M Co-Investigators: Carl Koschmann, MD; Patricia Robertson, MD; Marcia Leonard, NP; Rajen Mody, MD; Bernard Marini, PharmD; Hugh Garton, MD, MHSc.
Investigating epigenetic mechanisms which support DIPG tumor development through interrogation of the DIPG epigenome.
(clinical trial/immunotherapeutics)
Principal Investigator(s): Carl Koschmann, MD
U-M Co-Investigators: Sriram Venneti, MD, PhD
Collaborators: Susanne V. Schmidt, Dr.rer.nat. (Institute of Innate Immunity (iii), University Hospital, Bonn, Germany)
Therapeutic discovery in DIPG and pediatric high-grade glioma through a novel intra-uterine electroporation mouse model.
(drug delivery/device development; immunotherapy)
Principal Investigator: Carl Koschmann, MD
U-M Co-Investigators: Vivekanand Yadav, PhD; Sriram Venneti, MD, PhD; Tingting Qin, PhD
Therapeutically targeting ID1 in H3K27M-mutant DIPG
(pre-clinical/pathway; translational/therapy development)
Principal Investigator: Carl Koschmann, MD
U-M Co-Investigators: Sriram Venneti, MD, PhD; Rajen Mody, MD; Bing Ye, PhD; Tingting Qin, PhD
Collaborators: Cynthia Hawkins, MD, PhD (Sick Kids/Toronto); Sean McAllister, MD, PhD & Pierre Yves Desprez, PhD (CA Pacific Med Cntr Res Inst); Timothy Phoenix, PhD (Cincinnati Children’s Hosp Med Cntr)
Targeting Cancer Stem cells in Diffuse Intrinsic Pontine Glioma (DIPG)
(drug delivery/device development)
Principal Investigator: Stefanie Galbán, PhD
Team: Galbán Lab
Therapeutic Targeting of the Disrupted Metabolic State in DIPG to Induce Ferroptotic Cell Death
(fellowship)
Principal Investigator: Nneka E. Mbah, PhD
Team: Costas A. Lyssiotis, PhD (mentor); Sriram Venneti, M.D., PhD (co-mentor)
Targeting metabolic regulation of the epigenome in DIPG
(cellular therapy)
Principal Investigator(s): Sriram Venneti, MD, PhD
Team: Venneti Lab
Priming DIPG For Immunogenic Cell Death By Inducing Ferroptosis
(immunotherapeutics)
Principal Investigator(s): Costas A. Lyssiotis, PhD
U-M Co-Investigator(s): Maria Castro, PhD
Exploring the Androgen Receptor as a Therapeutic Target in Pediatric Brain Tumors
(clinical trial)
Principal Investigator(s): Daniel R Wahl, MD, PhD
U-M Co-Investigators: Carl Koschmann, MD; Sriram Venneti, MD, PhD; Ted Lawrence, MD, PhD
Precision Oncology in a Multi-institutional, Multi-Ethnic Cohort of Children with High-Risk Malignancies
(integrative clinical squencing)
Principal Investigator(s): Rajen Mody, MD, MS (Michigan Medicine) / Jeffrey W. Taub, MD, (Children’s Hospital of Michigan)
Collaborators: Michigan Medicine-UM Ann Arbor; Children’s Hospital of Michigan, Detroit; Hurley Medical Center, Flint
2018 Funded Projects
Michigan Medicine/ChadTough Foundation DIPG Genetic/Epigenetic Research Toolkit
(infrastructure)
Principal Investigator(s): Carl Koschmann, MD / Sriram Venneti, MD, PhD
U-M Co-Investigators: Rajen Mody, MD; Luigi Franchi, PhD; Valerie Opipari, MD; Patricia Robertson, MD; Arul Chinnaiyan, MD, PhD; Daniel Lawrence, PhD; Ted Lawrence, MD, PhD, Meredith Morgan, PhD; Maureen Sartor, PhD; Tingting Qin, PhD; Hugh Garton, MD, MHSc; Karin Muraszko, MD.
Collaborators: Cynthia Hawkins, MD, PhD (Toronto/Sick Kids), Maryam Fouladi, MD, MSc, FRCPC (Cincinnati Children’s), Amanda Saratsis, MD (Northwestern/Lurie Children’s), Chetan Bettegowda, MD, PhD and Ken Cohen, MD, MBA (Johns Hopkins), Chris Jones, Professor (Institute for Cancer Research, UK), Michelle Monje, MD, PhD (Stanford), Chao Lu, PhD (University of Columbia), C. David Allis, PhD (Rockefeller University).
Targeting metabolic reprogramming in H3K27M DIPGs
(cellular therapy)
Principal Investigator: Sriram Venneti, MD, PhD
U-M Co-Investigators: Costas Lyssiotis, PhD; Carl Koschmann, MD
Collaborators: Michelle Monje, MD, PhD (Stanford); Sophia Lunt, PhD (Michigan State)
A Phase 2 Study of ONC201 for Children and Young Adults with Gliomas Harboring H3K27M Mutation
(clinical trial)
Principal Investigator: Carl Koschmann, MD
U-M Co-Investigators: Patricia Robertson, MD; Marcia Leonard, NP; Rajen Mody, MD; Hugh Garton, MD, MD, MHSc; Abraham Van Der Spek, MD; Hemant Parmar, MD; Yue Cao, PhD; Bernard Marini, PharmD; Lili Zhao, PhD
Uncovering novel DNA-damage repair pathway targets in DIPG
(clinical trial/drug delivery/device development)
Principal Investigator(s): Carl Koschmann, MD / Meredith Morgan, MD
U-M Co-Investigators: Dan Lawrence, PhD; Ted Lawrence, MD, PhD; Alnawaz Rehemtulla, PhD; Sriram Venneti, MD, PhD
Collaborator: Timothy Phoenix, PhD, Cincinnati Children's Hospital Medical Center
Therapeutic targeting of the disrupted metabolic state in DIPG to induce ferroptotic cell death
(cellular therapy)
Principal Investigator: Costas Lyssiotis, PhD
U-M Co-Investigators: Luigi Franchi, PhD; Sriram Venneti, MD, PhD
2017 Funded Projects
Investigating a novel method of opening the blood brain barrier for treatment of DIPG
Drug Delivery Research
Principal Investigator: Daniel Lawrence, PhD
U-M Co-Investigators: Enming Su, PhD, Carl Koschmann, MD, Sriram Venneti, MD, PhD
H3K27M Interactome Mapping to Discover Novel DIPG Therapeutic Targets
Cellular Therapy Research
Principal Investigator: Sriram Venneti, MD, PhD
U-M Co-Investigators: Jean-Francois Rual, PhD, and Alexey I. Nesvizhskii, PhD
Collaborators: Michelle Monje, MD, PhD, Stanford University
Metabolic approaches to combat DIPG
Cellular Therapy Research
Principal Investigator: Sriram Venneti, MD, PhD
U-M Investigator: Costas Lyssiotis PhD
Collaborators: Michelle Monje, MD, PhD, Stanford University
CSF Digital Droplet PCR Analysis for DIPG Diagnosis and Therapy Response
Clinical Trial
Principal Investigator: Carl Koschmann, MD
Co-Investigators: Robert Dickson, MD, Benjamin Singer, MD, PhD
Comprehensive Genomic Characterization of DIPG to Guide Personalized Genomically Driven Therapy
Clinical Trial
Principal Investigator: Rajen Mody, MD, MS
U-M Co-Investigators: Arul Chinnaiyan, MD, PhD, Carl Koschmann, MD, Patricia Robertson, MD, Hugh Garton, MD, Marcin Cieslik, PhD, Sriram Venneti, MD, PhD
2016 Funded Projects - ChadTough Fund
Exploring role of ACVR1 and HIST1H3B Mutations in DIPG in vivo in Preclinical Mouse Models: Uncovering Novel Therapeutic Targets
Principal Investigator: Maria G. Castro
Co-Principal Investigator: Pedro R. Lowenstein
